LON:TILS

Tiziana Life Sciences Share Forecast, Price & News

GBX 83
0.00 (0.00 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
81.10
85
50-Day Range
70.50
101
52-Week Range
30
300
Volume231,782 shs
Average Volume662,161 shs
Market Capitalization£161.53 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TILS News and Ratings via Email

Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter.


Tiziana Life Sciences logo

About Tiziana Life Sciences

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops anti-IL6R (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients with severe respiratory symptoms. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.71 out of 5 stars

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Tiziana Life Sciences (LON:TILS) Frequently Asked Questions

What stocks does MarketBeat like better than Tiziana Life Sciences?

Wall Street analysts have given Tiziana Life Sciences a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tiziana Life Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Tiziana Life Sciences' earnings last quarter?

Tiziana Life Sciences PLC (LON:TILS) released its quarterly earnings results on Wednesday, September, 30th. The biotechnology company reported ($2.60) EPS for the quarter, topping the consensus estimate of ($4.00) by $1.40.
View Tiziana Life Sciences' earnings history
.

How has Tiziana Life Sciences' stock price been impacted by COVID-19?

Tiziana Life Sciences' stock was trading at GBX 85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TILS stock has decreased by 2.4% and is now trading at GBX 83.
View which stocks have been most impacted by COVID-19
.

Who are Tiziana Life Sciences' key executives?

Tiziana Life Sciences' management team includes the following people:
  • Mr. Gabriele Marco Antonio Cerrone M.B.A., MBA, Founder & Exec. Chairman (Age 49, Pay $284.56k)
  • Dr. Kunwar Shailubhai, CEO, Chief Scientific Officer & Exec. Director (Age 63, Pay $810k)
  • Dr. Andrea Brancale, Scientific Founder
  • Mr. Richard Clarkson Ph.D., Scientific Founder
  • Mr. Andrew Westwell Ph.D., Scientific Founder
  • Ms. Keeren Shah, Fin. Director (Age 44)
  • Dr. Thomas H. Adams, Head of Drug Devel. & Exec. Director (Age 78)
  • Dr. Neil Graham M.P.H., MBBS, M.D., MPH, Chief Medical Officer (Age 62)
  • Dr. Napoleone Ferrara, Chairman of Scientific Advisory Board (Age 63)
  • Prof. Roberto Pellicciari, Consultant

Who are some of Tiziana Life Sciences' key competitors?

What other stocks do shareholders of Tiziana Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tiziana Life Sciences investors own include Synergy Pharmaceuticals (SGYP), Micron Technology (MU), ServiceNow (NOW), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Broadcom (AVGO), Dropbox (DBX), Enterprise Products Partners (EPD) and Franco-Nevada (FNV).

What is Tiziana Life Sciences' stock symbol?

Tiziana Life Sciences trades on the London Stock Exchange (LON) under the ticker symbol "TILS."

How do I buy shares of Tiziana Life Sciences?

Shares of TILS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Tiziana Life Sciences' stock price today?

One share of TILS stock can currently be purchased for approximately GBX 83.

How much money does Tiziana Life Sciences make?

Tiziana Life Sciences has a market capitalization of £161.53 million.

How many employees does Tiziana Life Sciences have?

Tiziana Life Sciences employs 11 workers across the globe.

What is Tiziana Life Sciences' official website?

The official website for Tiziana Life Sciences is www.tizianalifesciences.com.

Where are Tiziana Life Sciences' headquarters?

Tiziana Life Sciences is headquartered at 3rd Fl, 11-12 St. James's Square, LONDON, SW1Y 4LB, United Kingdom.

How can I contact Tiziana Life Sciences?

Tiziana Life Sciences' mailing address is 3rd Fl, 11-12 St. James's Square, LONDON, SW1Y 4LB, United Kingdom. The biotechnology company can be reached via phone at +44-20-74952379.


This page was last updated on 6/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.